STOCK TITAN

Inmode Ltd. - INMD STOCK NEWS

Welcome to our dedicated page for Inmode Ltd. news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode Ltd. stock.

InMode Ltd. (NASDAQ: INMD) is a leading global provider of innovative medical technologies specializing in minimally and non-invasive surgical aesthetic and medical treatment solutions. The company's product portfolio spans three major energy-based treatment categories: face & body contouring, medical aesthetics, and women's health. Their products, such as BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, are widely utilized in plastic surgery, dermatology, gynecology, and ophthalmology.

InMode’s flagship products, including Fractora for skin texture improvement, Lumecca for photorejuvenation, Diolaze for hair removal, and BodyFX for body contouring, are designed to deliver effective and exciting aesthetic solutions.

InMode has consistently invested in research and development to expand its intellectual property portfolio, which is pivotal for maintaining its competitive edge. Recently, the company initiated legal action against BTL Industries for patent infringement regarding their radio-frequency based feminine rejuvenation products.

Despite market headwinds, including higher interest rates affecting equipment financing and slower purchase decisions, InMode has shown resilience with a 2% increase in Q3 2023 revenues, totaling $123.1 million. The company also saw a 13% rise in international sales during this period.

In Q1 2024, InMode announced pre-orders for two new platforms, IgniteRF and Optimus Max, which are anticipated to drive future growth. Additionally, a new share repurchase program and the appointment of Dr. Michael Anghel as Chairman of the Board underscore the company’s commitment to shareholder value.

InMode's innovative spirit is further highlighted by their recent partnership with P1 Offshore Racing, sponsoring the only female driver, Victoria Rand, signaling a strong commitment to empowering women.

For more detailed information and the latest updates, visit InMode's official website.

Rhea-AI Summary

InMode reported first quarter 2024 financial results, with a revenue of $80.3M representing a 24% YoY decrease. The company also announced a share repurchase program and appointed a new Chairman of the Board of Directors. Pro-forma revenue, including new platform pre-orders, was $96M. Quarterly revenues from consumables and service increased by 13%. GAAP net income was $23.7M, non-GAAP net income was $27.7M, and pro-forma non-GAAP net income was $38.8M. The company has a total cash position of $770.5M as of March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
-
Rhea-AI Summary
InMode responds to BTL's petition for Inter Partes Review of patent InMode is asserting against BTL, highlighting ongoing litigation and defense of their valuable technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
none
-
Rhea-AI Summary
InMode (NASDAQ: INMD) expects Q1 revenue between $80.0M-$80.1M, pro forma revenue (including new platform pre-orders) between $95.7M-$95.8M, and decreases FY 2024 guidance to $485M-$495M. Conference call scheduled for May 2, 2024, at 8:30 a.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.87%
Tags
conferences earnings
Rhea-AI Summary
InMode (INMD) announces participation in upcoming investor conferences and events in April and May, featuring key executives presenting at virtual and in-person events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
conferences
-
Rhea-AI Summary
InMode Ltd. (INMD) announces participation in key investor conferences in March 2024, showcasing top executives and presenting innovative medical technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
conferences
-
Rhea-AI Summary
InMode Ltd. (INMD) reports strong financial results for Q4 2023 and FY 2023 with record revenues, net income, and international growth. Quarterly revenue was $126.8 million, with a 20% increase in consumables and service revenue. Full-year revenue reached $492 million, with GAAP net income of $197.9 million and non-GAAP net income of $221.5 million. International revenues saw an 18% increase. The company's cash position stood at $741.6 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.65%
Tags
Rhea-AI Summary
InMode Ltd. (INMD) is set to release its financial results for the fourth quarter and full year 2023 on February 13, 2024. The company expects revenue for the fourth quarter to be between $126.0 million and $126.5 million, with full-year revenue in the range of $491.3 million to $491.8 million. Non-GAAP earnings per diluted share for the same periods are expected to be between $0.68 and $0.69, and $2.54 to $2.55, respectively. The company anticipates a non-GAAP gross margin for the full year of 2023 to be in the range of 83% to 85%. Additionally, InMode projects revenue for the full year 2024 to be between $495 million and $505 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
conferences earnings
-
News
Rhea-AI Summary
InMode Ltd. (INMD) revises its full-year 2023 guidance due to stronger-than-expected headwinds from the current macroeconomic environment, resulting in a slowdown in platform sales, mainly in North America. Revenue for the full year 2023 is expected to be in the range of $485-495 million, with non-GAAP gross margin remaining at 83-85% and non-GAAP income from operations in the range of $214-218 million. Non-GAAP earnings per diluted share for the full year 2023 are expected to be in the range of $2.47-2.50.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.99%
Tags
none
-
Rhea-AI Summary
InMode Ltd. (NASDAQ: INMD) will be participating in several investor conferences and events in November and December. The company will be presenting at the Jefferies London Healthcare Conference on Nov. 14 and participating in one-on-one meetings. In addition, InMode will be attending the Canaccord MTDF Investor Conference on Nov. 16 and the Mizuho Medical Device and Healthcare Services Summit on Dec. 6, both in New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.7%
Tags
conferences
Rhea-AI Summary
InMode Ltd. (Nasdaq: INMD) announced its Q3 2023 financial results. The company reported quarterly revenue of $123.1 million, a 2% increase compared to Q3 2022. InMode's proprietary surgical technology platforms accounted for 83% of revenues, followed by hands-free platforms at 9% and traditional laser and non-invasive RF platforms at 8%. The company's GAAP net income was $46.5 million, while non-GAAP net income was $53.1 million. Quarterly revenues from consumables and service reached $17.9 million, a 28% increase from Q3 2022. InMode's total cash position as of September 30, 2023, was $675.8 million, including cash, cash equivalents, marketable securities, and short-term bank deposits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.35%
Tags

FAQ

What is the current stock price of Inmode Ltd. (INMD)?

The current stock price of Inmode Ltd. (INMD) is $18.9 as of February 21, 2025.

What is the market cap of Inmode Ltd. (INMD)?

The market cap of Inmode Ltd. (INMD) is approximately 1.3B.

What products does InMode Ltd. offer?

InMode offers a range of innovative aesthetic solutions including BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8.

What are InMode's core business categories?

InMode's core business categories include face & body contouring, medical aesthetics, and women's health.

Which markets does InMode serve?

InMode serves markets including plastic surgery, dermatology, gynecology, and ophthalmology.

How did InMode perform in Q3 2023?

In Q3 2023, InMode reported revenues of $123.1 million, a 2% increase from the same period in 2022, and a 13% increase in international sales.

What are some of InMode's flagship products?

InMode's flagship products include Fractora, Lumecca, Diolaze, and BodyFX, offering solutions for skin texture improvement, photorejuvenation, hair removal, and body contouring.

What recent legal actions has InMode taken?

InMode filed a patent infringement complaint against BTL Industries concerning their radio-frequency based feminine rejuvenation products.

What new platforms has InMode recently announced?

InMode has announced pre-orders for two new platforms, IgniteRF and Optimus Max, expected to drive future growth.

Who is the new Chairman of InMode's Board?

Dr. Michael Anghel has been appointed as the new Chairman of InMode's Board, effective July 25, 2024.

What partnership has InMode recently entered into?

InMode partnered with P1 Offshore Racing and is sponsoring the only female driver, Victoria Rand, as part of Class 1.

Where can I find more information about InMode?

For more information and the latest updates, visit InMode's official website at https://inmodemd.com/.
Inmode Ltd.

Nasdaq:INMD

INMD Rankings

INMD Stock Data

1.32B
59.78M
12.72%
62.69%
7.49%
Medical Devices
Healthcare
Link
Israel
Yokne'am